Kevin Sayer would love to bring his company's Dexcom G7 continuous glucose monitor to more people and more quickly. But despite being CEO of a successful device company, he feels frustrated from time to time about how and what the U.S. health system will pay for.
U.S. healthcare is unnecessarily spending millions of dollars on scopes—dollars that could be better spent opening up new service lines, investing in medical equipment, or hiring nurses for improved patient care.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The innovator’s mindset is shifting from solving the problems right in front of us to solving problems once considered impossible to fix. The lines between curable and incurable diseases are blurring in surgery because medical devices are scaling up precision and scaling down the size of anatomy that surgeons can operate on.
This year's J.P. Morgan Healthcare Conference brought a bevy of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for seven of the event’s most notable announcements.
From its heady unicorn days to being newly public to its current financial struggles, the portable ultrasound-on-a-chip company has seen it all. Now, its latest CEO has his work cut out for him. A return to revenue growth is what Joseph DeVivo is promising this year.
Each track will spotlight a different specialty area including: oncology, cardiology, women's health and preventing burnout/supporting operational efficiency.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Medical device giant Boston Scientific added to its string of recent acquisitions by announcing its plan to buy Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $3.7 billion. Experts agree that this deal will make a profitable impact on Boston Scientific’s urology business.
Geoff Martha sought to establish a clear line between popular understanding of AI created by apps like ChatGPT and what he believes is the significant impact that Medtronic's AI-enabled products are already having on patients and other healthcare stakeholders today.
It’s high time we reframe how we think about lung cancer by ending the shame and judgment. I care less about if you quit smoking, I care more that you get screened. No one should have to die, period.
Contraline released promising data from the clinical trial it’s conducting to test the efficacy of Adam, its male birth control product. The nonhormonal gel seems to be doing a good job of blocking the flow of sperm to the vas deferens, and no serious adverse events have been reported.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
The evolution of ECMO from a last-resort intervention to a mainstay of modern critical care is a testament to the relentless pursuit of better patient outcomes in the field of medicine. Unfortunately, despite the immense life-saving capability of this therapy, it remains vastly underutilized.
Medical device startup CardioMech raised $13 million to advance the development and validation of its flagship device, which is designed to treat degenerative mitral valve regurgitation. The catheter-based device seeks to offer an uncomplicated, direct procedure for patients eligible for open-heart surgery as well as those considered eligible for the surgery.
At RSNA, three major trends stood out: the integration of artificial intelligence (AI), a renewed focus on health equity, and a dedicated effort to enhance the patient experience.
Butterfly Network announced a product co-development deal with surgical robotics startup Mendaera, in which the startup will build custom robotics around Butterfly’s ultrasound-on-a-chip technology to create a new system designed for better surgical precision and consistency. Both partners expect to complete the product’s FDA submission by 2025.
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024.